Drug Trial Radar · NCT06516068
A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Actual
Start
Aug 11, 2024
Primary completion
Nov 18, 2024
Study completion Aug 2025
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy
Conditions
- Obstructive Hypertrophic Cardiomyopathy
Interventions
HRS-1893Drug
HRS-1893
Primary outcomes
What the sponsor says the trial is designed to measure.
- The subjects' left ventricular outflow tract pressure gradient (Valsalva LVOT-G) was assessed for changes from the baseline after performing the Valsalva maneuverTime frame: After 12 weeks of HRS-1893 treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.